 |
|
|
| |
Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients:
The Randomized Controlled Phase 3 ASTRAL-3 Study
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 17 San Francisco
Alessandra Mangia1, Stuart K. Roberts2, Stephen Pianko3, Alex Thompson4, Curtis Cooper5, Brian Conway6, Marc Bourliere7, Tarik Asselah8, Thomas Berg9, Stefan Zeuzem10, William Rosenberg11, Kosh Agarwal12, Edward J. Gane13, Catherine Stedman14, Francesco Mazzotta15, Tram T. Tran16, Stuart Gordon17, Evguenia Svarovskaia18, Lingling Han18, John McNally18, Anu Osinusi18, Diana M. Brainard18, John G. McHutchison18, Nezam Afdhal19, Graham R. Foster20
1Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 2Alfred Health and Monash University, Prahran, Victoria, Australia; 3Monash Health and Monash University, Clayton, Victoria, Australia; 4St Vincent's Hospital, Melbourne, Victoria, Australia; 5Ottawa General Hospital, Ottawa, Ontario, Canada; 6Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; 7Hôpital Saint Joseph, Marseille, France; 8University Paris Diderot, INSERM U773, Paris, France; 9Leipzig University Hospital, Germany; 10 Johann Wolfgang Goethe University, Frankfurt, Germany; 11University College London, UK; 12Kings College Hospital, London, UK; 13Auckland Clinical Studies, New Zealand; 14Christchurch Clinical Studies Trust and University of Otago, Christchurch, New Zealand; 15Santa Maria Annunziata Hospital, Florence, Italy; 16Cedars-Sinai Medical Center, Los Angeles, CA; 17Henry Ford Health System, Detroit, MI; 18Gilead Sciences, Inc., Foster City, CA; 19Beth Israel Deaconess Medical Center, Boston, MA; 20Queen Mary University of London, UK
|
| |
|
|
|
|
|
